292 related articles for article (PubMed ID: 10372792)
21. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions.
Liester MB; Prickett JI
J Psychoactive Drugs; 2012; 44(3):200-8. PubMed ID: 23061319
[TBL] [Abstract][Full Text] [Related]
22. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
Heise CW; Brooks DE
J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660
[TBL] [Abstract][Full Text] [Related]
23. Ayahuasca for the Treatment of Depression.
Palhano-Fontes F; Soares BL; Galvão-Coelho NL; Arcoverde E; Araujo DB
Curr Top Behav Neurosci; 2022; 56():113-124. PubMed ID: 34761362
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
[TBL] [Abstract][Full Text] [Related]
25. Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment.
Brierley DI; Davidson C
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):263-72. PubMed ID: 22691716
[TBL] [Abstract][Full Text] [Related]
26. Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease.
Wang YH; Samoylenko V; Tekwani BL; Khan IA; Miller LS; Chaurasiya ND; Rahman MM; Tripathi LM; Khan SI; Joshi VC; Wigger FT; Muhammad I
J Ethnopharmacol; 2010 Apr; 128(3):662-71. PubMed ID: 20219660
[TBL] [Abstract][Full Text] [Related]
27. Identification of N,N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage.
Gambelunghe C; Aroni K; Rossi R; Moretti L; Bacci M
Biomed Chromatogr; 2008 Oct; 22(10):1056-9. PubMed ID: 18506697
[TBL] [Abstract][Full Text] [Related]
28. Ayahuasca: Pharmacology, neuroscience and therapeutic potential.
Domínguez-Clavé E; Soler J; Elices M; Pascual JC; Álvarez E; de la Fuente Revenga M; Friedlander P; Feilding A; Riba J
Brain Res Bull; 2016 Sep; 126(Pt 1):89-101. PubMed ID: 26976063
[TBL] [Abstract][Full Text] [Related]
29. Components of
Santos BWL; Moreira DC; Borges TKDS; Caldas ED
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458698
[No Abstract] [Full Text] [Related]
30. The globalization of ayahuasca: harm reduction or benefit maximization?
Tupper KW
Int J Drug Policy; 2008 Aug; 19(4):297-303. PubMed ID: 18638702
[TBL] [Abstract][Full Text] [Related]
31. Ritualistic Use of Ayahuasca versus Street Use of Similar Substances Seized by the Police: A Key Factor Involved in the Potential for Intoxications and Overdose?
Lanaro R; Calemi DB; Togni LR; Costa JL; Yonamine M; Cazenave Sde O; Linardi A
J Psychoactive Drugs; 2015; 47(2):132-9. PubMed ID: 25950593
[TBL] [Abstract][Full Text] [Related]
32. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat.
Pic-Taylor A; da Motta LG; de Morais JA; Junior WM; Santos Ade F; Campos LA; Mortari MR; von Zuben MV; Caldas ED
Behav Processes; 2015 Sep; 118():102-10. PubMed ID: 26049017
[TBL] [Abstract][Full Text] [Related]
33. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.
Rossi GN; Guerra LTL; Baker GB; Dursun SM; Saiz JCB; Hallak JEC; Dos Santos RG
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358968
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease.
Katchborian-Neto A; Santos WT; Nicácio KJ; Corrêa JOA; Murgu M; Martins TMM; Gomes DA; Goes AM; Soares MG; Dias DF; Chagas-Paula DA; Paula ACC
J Ethnopharmacol; 2020 Jun; 255():112743. PubMed ID: 32171895
[TBL] [Abstract][Full Text] [Related]
35. Toxicological Aspects and Determination of the Main Components of Ayahuasca: A Critical Review.
Simão AY; Gonçalves J; Duarte AP; Barroso M; Cristóvão AC; Gallardo E
Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31635364
[TBL] [Abstract][Full Text] [Related]
36. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.
Morales-García JA; de la Fuente Revenga M; Alonso-Gil S; Rodríguez-Franco MI; Feilding A; Perez-Castillo A; Riba J
Sci Rep; 2017 Jul; 7(1):5309. PubMed ID: 28706205
[TBL] [Abstract][Full Text] [Related]
37. Pharmahuasca: human pharmacology of oral DMT plus harmine.
Ott J
J Psychoactive Drugs; 1999; 31(2):171-7. PubMed ID: 10438001
[TBL] [Abstract][Full Text] [Related]
38. Various alkaloid profiles in decoctions of Banisteriopsis caapi.
Callaway JC
J Psychoactive Drugs; 2005 Jun; 37(2):151-5. PubMed ID: 16149328
[TBL] [Abstract][Full Text] [Related]
39. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.
Riba J; Rodríguez-Fornells A; Barbanoj MJ
Psychopharmacology (Berl); 2002 Dec; 165(1):18-28. PubMed ID: 12474114
[TBL] [Abstract][Full Text] [Related]
40. Light microscopy can reveal the consumption of a mixture of psychotropic plant and fungal material in suspicious death.
Wiltshire PE; Hawksworth DL; Edwards KJ
J Forensic Leg Med; 2015 Aug; 34():73-80. PubMed ID: 26165663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
